294877-29-5

Usage

Uses

Used in Organic Synthesis:
1-(3-Bromophenyl)-3,5-dimethyl-1H-pyrazole is utilized as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique structure allows for the formation of new chemical entities through reactions such as coupling, substitution, and functional group transformations.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 1-(3-Bromophenyl)-3,5-dimethyl-1H-pyrazole serves as a valuable building block for the development of new drugs. Its versatile chemical properties enable the creation of novel drug candidates with potential therapeutic applications in various medical fields.
Used in Agrochemical Development:
1-(3-Bromophenyl)-3,5-dimethyl-1H-pyrazole is also considered for its potential applications in the development of agrochemicals. Its unique structure and properties may contribute to the design of new pesticides, herbicides, or other agricultural chemicals that can improve crop protection and yield.
Used in Specialized Chemicals:
1-(3-Bromophenyl)-3,5-dimethyl-1H-pyrazole's unique characteristics make it suitable for use in the development of specialized chemicals for various industrial applications. Its potential uses may include the creation of new materials, dyes, or other chemical products with specific properties tailored to meet industry needs.

Upstream product

• 123-54-6 acetylacetone 
• 40887-80-7 3-bromophenylhydrazine 
• 67-51-6 3,5-dimethyl-1H-pyrazole 
• 591-18-4 1-Bromo-3-iodobenzene 
• 27246-81-7 3-bromophenylhydrazine hydrochloride 

Downstream Products

• 1393812-50-4 2-[3-(3,5-dimethylpyrazol-1-yl)-phenoxy]-N-(tetrahydropyranyl)carbazole 

Relevant academic research and scientific papers

Organometallic compound, organic light-emitting device including the same and apparatus including the same

Provided are an organometallic compound, an organic light-emitting device including the organometallic compound, and an apparatus including the organometallic compound. The organic light-emitting device includes a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode and including an emission layer, wherein the organic layer includes the organometallic compound.

Oxone-DMSO Triggered Methylene Insertion and C(sp2)-C(sp3)-H-C(sp2) Bond Formation to Access Functional Bis-Heterocycles

Metal-free insertion of a methylene group was achieved for the construction of a new C(sp2)-C(sp3)-H-C(sp2) bond in order to prepare novel bis-heterocyclic scaffolds. The complete mechanistic investigations included experimental study and DFT calculations, and various symmetric and unsymmetric bis-pyrazoles as well as other pyrazole-based bis-heterocyclic molecules were prepared in moderate to high yields. Further modification of the bridged methylene group in the unsymmetric pyrazoles generated a chiral center to extend the scope of this method.

Phenyl bridged pyrazole benzimidazole derivative and preparation method thereof

The invention discloses a phenyl bridged pyrazole benzimidazole derivative and a preparation method thereof. The phenyl bridged pyrazole benzimidazole derivative is synthesized by using 3-bromophenylhydrazine as a raw material through a three-step reaction. The compound provided by the invention can be used as a tridentate ligand for synthesis of a ruthenium complex with high catalytic activity. The preparation method provided by the invention has the advantages of cheap and easily-available raw materials, high synthetic efficiency, easy product derivatization, etc.

Synthesis and determination of absolute configuration of a non-peptidic αvβ6 integrin antagonist for the treatment of idiopathic pulmonary fibrosis

A diastereoselective synthesis of (S)-3-(3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl)-4-((R)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl)pyrrolidin-1-yl)butanoic acid (1), a potential therapeutic agent for the treatment of Idiopathic Pulmonary Fibrosis, which is currently undergoing Phase I clinical trials is reported. The key steps in the synthesis involved alkylation of 2-methylnaphthyridine with (R)-N-Boc-3-(iodomethyl)-pyrrolidine, and an asymmetric Rh-catalysed addition of an arylboronic acid to a 4-(N-pyrrolidinyl)crotonate ester. The overall yield of the seven linear step synthesis was 8% and the product was obtained in >99.5% ee proceeding with 80% de. The absolute configuration of 1 was established by an alternative asymmetric synthesis involving alkylation of an arylacetic acid using Evans oxazolidinone chemistry, acylation using the resulting 2-arylsuccinic acid, and reduction. The absolute configuration of the benzylic asymmetric centre was established as (S).

NAPHTHYRIDINE DERIVATIVES USEFUL AS ALPHA-V-BETA-6 INTEGRIN ANTAGONISTS

A compound of formula (I) or a salt thereof (I) wherein R1 represents a hydrogen atom, a methyl group or a ethyl group R2 represents a hydrogen atom or a fluorine atom R3 represents a hydrogen atom, a methyl group or an ethyl group.